Page last updated: 2024-11-06

corticosterone and ACTH-Producing Pituitary Adenoma

corticosterone has been researched along with ACTH-Producing Pituitary Adenoma in 4 studies

Research Excerpts

Excerpt	Relevance	Reference
"Gefitinib treatment decreased both tumor size and corticosterone levels; it also reversed signs of hypercortisolemia, including elevated glucose levels and excess omental fat."	1.37	EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. ( Ben-Shlomo, A; Bruyette, D; Cooper, O; Fukuoka, H; Mamelak, A; Melmed, S; Ren, SG, 2011)

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Asari, Y	1
Kageyama, K	1
Sugiyama, A	1
Kogawa, H	1
Niioka, K	1
Daimon, M	1
Du, L	1
Bergsneider, M	1
Mirsadraei, L	1
Young, SH	1
Jonker, JW	1
Downes, M	1
Yong, WH	1
Evans, RM	1
Heaney, AP	1
Liu, NA	1
Jiang, H	1
Ben-Shlomo, A	2
Wawrowsky, K	1
Fan, XM	1
Lin, S	1
Melmed, S	2
Fukuoka, H	1
Cooper, O	1
Mamelak, A	1
Ren, SG	1
Bruyette, D	1

Clinical Trials (2)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease[NCT03774446]	Phase 2	13 participants (Anticipated)	Interventional	2018-11-02	Recruiting
Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine[NCT02160730]	Phase 2	4 participants (Actual)	Interventional	2014-05-31	Terminated (stopped due to NIH grant ended.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants That Experience Changes in Clinical Signs of Hypercortisolemia

The number of participants that achieved a urinary free cortisol level above the upper limit of the normal range but reduced by ≥50% from baseline at week 4. (NCT02160730)
Timeframe: Baseline, Week 4

Intervention	Participants (Count of Participants)
R-roscovitine	2

Number of Participants That Have a Visible Change in Tumor Size

A visible change in tumor size as determined by the investigator after reviewing MRI reports between baseline and 4 weeks of treatment. (NCT02160730)
Timeframe: Baseline, 4 weeks

Intervention	Participants (Count of Participants)
R-roscovitine	0

Number of Participants With a Normalized 24 Hour Urinary Free Cortisol After 4 Weeks

"To evaluate the efficacy of R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks on normalizing 24 hour urinary free cortisol (24 h UFC) levels in CD patients. Normalizing is defined as having urine free cortisol levels within the normal range for that lab value." (NCT02160730)
Timeframe: Baseline, 4 weeks

Intervention	Participants (Count of Participants)
R-roscovitine	0

Number of Participants With Adverse Events

The number of participants that experience an adverse event between baseline and study end likely related to study drug as a measure of safety and tolerability. (NCT02160730)
Timeframe: Baseline, 4 weeks

Intervention	Participants (Count of Participants)
R-roscovitine	2

Change in Clinical Symptoms

Change in typical Cushing's syndrome clinical signs and symptoms defined by mean weight at baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks

Intervention	lbs (Mean)
	Baseline	4 Weeks
R-roscovitine	217	217.4

Change in Diastolic Blood Pressure

Mean diastolic blood pressure between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks

Intervention	mmHg (Mean)
	Baseline	4 Weeks
R-roscovitine	76.5	71

Change in Mean HbA1c Levels Between Baseline and 4 Weeks

HbA1c levels are measured at baseline and at study end, these are averaged across all subjects. (NCT02160730)
Timeframe: Baseline, 4 Weeks

Intervention	Percentage (Mean)
	Baseline	Study End-4 weeks
R-roscovitine	6.9	7

Change in Systolic Blood Pressure

Mean change in systolic blood pressure between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks

Intervention	mmHg (Mean)
	Baseline	4 weeks
R-roscovitine	150.3	128.3

Changes in Serum Cortisol Between Baseline and 4 Weeks

Mean serum cortisol values at baseline and 4 weeks (NCT02160730)
Timeframe: Baseline, 4 weeks

Intervention	mg/dL (Mean)
	Baseline	4 Weeks
R-roscovitine	25.6	27.1

Fasting Glucose at Baseline and 4 Weeks

Mean change between baseline and week 4 of fasting blood glucose levels. (NCT02160730)
Timeframe: Baseline, 4 Weeks

Intervention	g/dL (Mean)
	Baseline	4 weeks
R-roscovitine	121.4	104.3

Plasma ACTH at Baseline and 4 Weeks

Mean change in Plasma ACTH between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks

Intervention	pg/mL (Mean)
	Baseline	4 weeks
R-roscovitine	79.3	79.9

Other Studies

4 other studies available for corticosterone and ACTH-Producing Pituitary Adenoma

Article	Year
Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells. Endocrine journal, 2019, Jun-28, Volume: 66, Issue:6 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Animals; Antineoplastic Agen	2019
Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, May-21, Volume: 110, Issue:21 Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Animals; Cell Line, Tumor; Cell Proli	2013
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2011, May-17, Volume: 108, Issue:20 Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Animals; Animals, Genetically Modifie	2011
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2011, May-17, Volume: 108, Issue:20 Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Animals; Animals, Genetically Modifie	2011
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2011, May-17, Volume: 108, Issue:20 Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Animals; Animals, Genetically Modifie	2011
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2011, May-17, Volume: 108, Issue:20 Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Animals; Animals, Genetically Modifie	2011
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. The Journal of clinical investigation, 2011, Volume: 121, Issue:12 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Animals; Cell Line, Tumor; C	2011